Search
for

    Glossary Tocilizumab

    medication that inhibits IL-6 receptor to reduce inflammation

    Tocilizumab, also known by the brand name Actemra, is a medication that targets the interleukin-6 (IL-6) receptor, which plays a role in the body's immune response. It is commonly used to treat autoimmune conditions such as rheumatoid arthritis and has also been explored for use in managing severe cases of COVID-19. By inhibiting IL-6, Tocilizumab helps reduce inflammation and modulate the immune system.

    Research 10 of 124

    1. Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy Oxford Medical Case Reports · 2016 · 10 citations
    2. Hair-cycle changes in two patients taking tocilizumab Joint Bone Spine · 2013 · 6 citations
    3. Hair Growth in a Patient with Alopecia Areata on Tocilizumab Skin appendage disorders · 2021 · 1 citations
    4. EVIDÊNCIAS ACERCA DO USO DO ANTICORPO MONOCLONAL TOCILIZUMABE COMO TERAPÊUTICA PARA COVID-19 Amplla Editora eBooks · 2022
    5. Telogen effluvium related to post severe Sars‐Cov‐2 infection: Clinical aspects and our management experience Dermatologic Therapy · 2020 · 35 citations
    6. Commonalities Between COVID-19 and Radiation Injury Radiation Research · 2020 · 18 citations
    7. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients Joint Bone Spine · 2013 · 14 citations
    8. Polymorphism of genes in patients with new coronavirus infection COVID-19 Infectious diseases News Opinions Training · 2022 · 8 citations
    9. Lichen Planopilaris in Children: A Systematic Review Pediatric Dermatology · 2024 · 3 citations
    10. Unravelling Beau's lines as a potential indicator of severe immune response in COVID-19 and reinfection European Journal of Case Reports in Internal Medicine · 2024 · 2 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →